Surgery is the cornerstone of vulvar cancer treatment, but the specific plan depends on the tumor’s size, location, stage, and molecular profile. Small, early-stage tumors may need only a wide local excision and a sentinel lymph node check, while advanced disease can require a combination of radical surgery, radiation, and chemotherapy. Treatment decisions also hinge on histology, imaging findings, and increasingly on whether the cancer is linked to human papillomavirus (HPV) or carries certain genetic mutations.
Surgery for Early-Stage Disease
For most people diagnosed with vulvar cancer, the first-line treatment is surgical removal of the tumor. The goal is to excise the lesion with a surrounding margin of healthy tissue wide enough to minimize recurrence. How much tissue needs to come out varies. A small, unifocal tumor can be treated with a radical wide local excision, where the surgeon removes the cancer with a cuff of normal tissue around it. More extensive disease may call for a partial or complete vulvectomy, though surgeons increasingly favor the most conservative operation that still achieves clear margins, since removing less tissue preserves anatomy and function.
Surgical margins matter a great deal. An Australian retrospective study found that margins under 5 mm roughly doubled the risk of any vulvar recurrence compared to wider margins. Even margins between 5 and just under 8 mm carried a substantially higher risk of the cancer coming back at the original site, though interestingly that group had a lower chance of distant recurrence.1PubMed Central. The Prognostic Role of the Surgical Margins in Squamous Vulvar Cancer: A Retrospective Australian Study These findings help explain why guidelines for radiation after surgery often use 8 mm as a key threshold: margins narrower than that are considered a reason to add radiation to reduce the chance of local recurrence.2PubMed Central. Adjuvant Radiation in Early Stage Vulvar Cancer: A Review of Indications and Optimal Dose
Checking the Lymph Nodes
Vulvar cancer spreads first to the inguinal (groin) lymph nodes, so figuring out whether cancer has reached those nodes is critical for staging and deciding on further treatment. The traditional approach was a full inguinofemoral lymph node dissection, which removes a large number of nodes from both groins. It is effective but carries a heavy toll in side effects, especially chronic leg swelling.
Sentinel lymph node biopsy has become a standard alternative for early-stage tumors under 4 cm. The concept is straightforward: surgeons inject a tracer around the tumor to identify the first node or nodes that drain from it. If those sentinel nodes are cancer-free, the remaining nodes are overwhelmingly likely to be clear, and the full dissection can be skipped. In a landmark international study, patients with negative sentinel nodes who skipped the full dissection had a three-year survival rate of 97% and a groin recurrence rate of only about 2%, while experiencing far less lymphedema and wound trouble than they would have with a complete dissection.3PubMed Central. Current Limitations of Sentinel Node Biopsy in Vulvar Cancer
A meta-analysis looking at sentinel node accuracy across multiple studies reported a false-negative rate of about 6%, meaning a small percentage of patients with cancer in the nodes will be missed by the sentinel approach alone.4Gynecologic Oncology. Sentinel lymph node biopsy in vulvar cancer: Systematic review, meta-analysis and guideline recommendations That rate drops lower when the tumor is small and the technique includes both a radiotracer and blue dye. For larger or multifocal tumors, or when the sentinel node comes back positive, a full node dissection is still recommended.
When Radiation Is Added After Surgery
Radiation therapy after surgery, called adjuvant radiation, is not routine for every patient. It is typically recommended when the surgical margins are close or positive (cancer cells at the edge of the removed tissue), or when cancer has spread to two or more lymph nodes. Both of those scenarios significantly raise the risk of the disease coming back.2PubMed Central. Adjuvant Radiation in Early Stage Vulvar Cancer: A Review of Indications and Optimal Dose The radiation field covers the vulvar surgical bed, the groin nodes, or both, depending on where the risk is highest.
One ongoing debate is the ideal dose. There is broad agreement that adjuvant radiation reduces local recurrence in high-risk patients, but the optimal number of treatments and total dose have not been pinned down by a large randomized trial. In practice, most centers deliver between 45 and 60 Gy over several weeks, with the higher end reserved for positive margins where a re-excision is not feasible.
Chemoradiation for Advanced or Unresectable Tumors
When vulvar cancer is locally advanced, meaning it involves nearby structures like the urethra, anus, or vagina to a degree that would require removing those organs, chemoradiation becomes a serious option. The idea is to use radiation combined with chemotherapy drugs (typically cisplatin, sometimes with 5-fluorouracil) to shrink the tumor enough that surgery can spare those organs, or to control the disease without surgery entirely.5PubMed Central. Role of Chemotherapy in Vulvar Cancers: Time to Rethink Standard of Care?
Evidence comparing chemoradiation head-to-head with primary surgery for advanced vulvar cancer remains thin. A Cochrane review found no clear survival advantage for neoadjuvant chemoradiation over primary surgery, though the studies were small.6PubMed Central. Chemoradiation for advanced primary vulval cancer In practice, the choice often comes down to anatomy: if upfront surgery would mean a colostomy bag or urinary diversion, many teams try chemoradiation first to avoid that outcome. A single-institution series reported that about a third of patients with urethral involvement and more than half of those with anal involvement were able to avoid amputation or colostomy after receiving chemotherapy before surgery.7PubMed. Neoadjuvant chemotherapy followed by radical surgery in locally advanced vulvar carcinoma: a single-institution experience
Chemotherapy on Its Own
Standalone chemotherapy plays a more limited role in vulvar cancer compared to many other cancers. It is used mainly in two scenarios: as part of neoadjuvant treatment before surgery (as described above), and in metastatic or recurrent disease when surgery and radiation are no longer viable options. The most common regimens pair a platinum drug like cisplatin or carboplatin with a taxane or with 5-fluorouracil.5PubMed Central. Role of Chemotherapy in Vulvar Cancers: Time to Rethink Standard of Care? Response rates exist but are generally modest, and no single chemotherapy regimen has been established as clearly superior through large randomized trials. This is one of the areas where the field most needs new data.
Reconstructive Surgery After Vulvectomy
Removing a large section of vulvar tissue creates a wound that is difficult to close directly, especially when the defect extends across both sides or involves the perineum. Reconstructive flap surgery is the standard solution. The surgeon mobilizes adjacent skin and tissue to fill the gap, restoring coverage and, ideally, some degree of normal sensation and contour.
Several flap types are used. One retrospective series of 26 patients found that rhomboid flaps were the most commonly chosen design for both primary and recurrent cases, with poor wound healing as the most frequent complication, occurring in about 8% of flaps. Reassuringly, prior surgery or radiation did not increase complication rates in that series.8PubMed Central. Experience with flap repair after vulvar carcinoma resection: a retrospective observational study of 26 cases A separate group described keystone flaps that incorporate blood vessels and nerves from three named arteries, achieving good sensation and function across a variety of defect shapes.9PubMed Central. Vulvar Reconstruction Using Keystone Flaps Based on the Perforators of Three Arteries The choice of flap depends on the size, shape, and location of the defect; most surgeons prefer local tissue whenever possible because it heals faster and looks more natural than grafts brought from distant sites.
Lymphedema and Other Surgical Side Effects
Lower-limb lymphedema is one of the most impactful complications after vulvar cancer surgery, particularly after a full inguinofemoral lymph node dissection. Fluid accumulates in one or both legs because the lymph drainage pathways have been disrupted. The swelling can be mild and manageable with compression garments, or severe enough to limit mobility and daily life. A study comparing quality of life in vulvar cancer patients found a strong link between the severity of leg swelling and worse scores across physical, emotional, social, and even financial domains.10PubMed. Quality of life in women with vulvar cancer submitted to surgical treatment: a comparative study
There is growing interest in preventive microsurgery performed at the time of node dissection, where a surgeon connects severed lymph vessels to small veins to keep drainage flowing. In a small pilot study, patients who received this preventive procedure had lower rates of lymphedema during follow-up than those who did not, though the study was too small to draw firm conclusions.11International Journal of Gynecological Cancer. Lymphedema Microsurgical Preventive Healing Approach for Primary Prevention of Lower Limb Lymphedema After Inguinofemoral Lymphadenectomy for Vulvar Cancer The sentinel node approach discussed earlier sidesteps much of this problem entirely by avoiding the full dissection when nodes are negative.
Beyond lymphedema, wound breakdown is common because the vulvar and groin regions are warm, moist, and subject to friction. Wound-healing complications were associated with reduced overall quality of life in a study of patients treated with vulvar field resection, an effect that was amplified when preexisting health conditions were also present.12PubMed Central. Quality of life and associated factors after surgical treatment of vulvar cancer by vulvar field resection (VFR)
Sexual Function and Emotional Recovery
Vulvar cancer treatment affects a part of the body closely tied to sexual identity and function, and the impact is real and often underaddressed. A Norwegian cross-sectional study found that only about 20% of vulvar cancer survivors were sexually active, compared to roughly 69% of age-matched women in the general population, and those who were active reported more sexual difficulties.13PubMed Central. Long-term quality of life, vulvar symptoms, and sexual functioning: A cross-sectional study of Norwegian vulvar cancer survivors Changes in anatomy, scarring, altered sensation, and psychological distress all contribute.
Early and structured rehabilitation can make a difference. In one study that enrolled patients in a postoperative rehabilitation program focused on psycho-emotional support and sexual function, the share of women reporting pain during intercourse dropped from 25% to about 4% over the first year in the rehabilitation group, compared to a smaller drop in those who did not receive the program. Improvements in desire and satisfaction were also more common among the rehabilitated group.14Obstetrics, Gynecology and Reproduction. Effect of postoperative rehabilitation on quality of life in patients with vulvar cancer The takeaway is that asking about sex and offering structured support should be part of routine follow-up, not something left for the patient to raise on her own.
How HPV and p53 Status Are Reshaping Treatment Thinking
Vulvar squamous cell carcinoma is not one disease. Molecular classification based on HPV infection and the status of the p53 tumor suppressor gene has identified three distinct subtypes with meaningfully different outcomes. In a large Dutch study of 413 tumors, about 18% were HPV-positive, 15% were HPV-negative with normal p53, and 66% were HPV-negative with mutated p53. Patients in the HPV-positive group had the best outcomes. Those in the HPV-negative/p53-mutated group had the worst overall and recurrence-free survival, with roughly three to four times the risk of recurrence compared to HPV-positive patients.15PubMed. Vulvar cancer subclassification by HPV and p53 status results in three clinically distinct subtypes
A separate study confirmed that both HPV-negative subtypes had worse recurrence-free survival than HPV-positive tumors, with the HPV-negative/p53-normal group showing the worst recurrence-free survival but somewhat better disease-specific survival than the p53-abnormal group, suggesting the subtypes behave differently even beyond the HPV-positive versus HPV-negative divide.16PubMed. Human papillomavirus and p53 status define three types of vulvar squamous cell carcinomas with distinct clinical, pathological, and prognostic features
Right now, all subtypes still receive the same surgical and radiation treatments. But there is a strong push to change that. The argument is that HPV-positive tumors, with their better prognosis, might safely receive less aggressive treatment, while HPV-negative/p53-mutated tumors might benefit from intensified approaches or novel targeted therapies. Incorporating molecular classification into treatment decisions has been highlighted as one of the most promising near-term advances in vulvar cancer management.17PubMed. Advances in Vulvar Cancer Biology and Management
When Cancer Comes Back
Recurrence is unfortunately common in vulvar cancer, and how it is managed depends heavily on where it reappears. Isolated vulvar recurrences, meaning the cancer returns at or near the original site without spreading to nodes or distant organs, account for up to half of all recurrences. These are often curable with another surgical excision.18PubMed. Local and regional recurrence of vulval cancer: management dilemmas Larger recurrent tumors that involve surrounding structures like the bladder or rectum may require more extensive operations, and chemoradiation is sometimes used before surgery or as palliative treatment when a cure is no longer realistic.
Groin recurrences carry a worse prognosis than local vulvar recurrences. They are harder to treat surgically because the area has often already been dissected and possibly irradiated. Distant metastases are managed primarily with systemic chemotherapy, though response rates remain modest.
Paget’s Disease and Other Rare Subtypes
Not all vulvar cancers are squamous cell carcinomas. Extramammary Paget’s disease of the vulva is a rare, slow-growing skin cancer seen mainly in postmenopausal women. It presents as red, scaly patches that can look deceptively benign and often spread microscopically well beyond the visible edges of the lesion. Surgery is the primary treatment, but achieving clear margins is a persistent challenge because of that hidden spread.19PubMed Central. Interventions for the treatment of Paget’s disease of the vulva Some centers have adopted techniques like the “spaghetti technique,” where thin strips of tissue are taken from all edges of the lesion, the wound is loosely closed, and final margin status is checked on detailed pathology before completing the repair.20PubMed Central. Deferred Lateral Margin Control in the Surgical Treatment of Genital Paget’s Disease and Lentiginous Vulvar Melanoma
Vulvar melanoma is another rare subtype, accounting for a small fraction of vulvar cancers. It tends to occur on mucosal surfaces and behaves more aggressively than cutaneous melanoma elsewhere on the body. Treatment follows melanoma-specific principles, including wide excision and, increasingly, immunotherapy with checkpoint inhibitors for advanced disease.
Follow-Up After Treatment
Because recurrence risk is real and many recurrences are treatable if caught early, structured follow-up is important. According to a comparison of international guidelines, the NCCN recommends visits every three to six months for the first two years, then every six to twelve months out to five years, and annually after that. Patients at higher risk may be seen as often as every three months during the first two years.21PubMed Central. Management of Patients with Vulvar Cancers: A Systematic Comparison of International Guidelines Imaging and lab tests are generally reserved for when symptoms or physical examination raise concern, rather than done routinely. Patients should know what signs to watch for between visits, including any new lumps, skin changes, or persistent itching or pain in the treated area.
Fertility Preservation in Younger Patients
Vulvar cancer is most common in older women, but it does occur in younger patients who may want to have children. Vulvar surgery itself does not directly affect fertility because it does not involve the uterus or ovaries. The challenge arises when radiation is needed, because pelvic radiation can damage the ovaries and vaginal tissues. In a published case of a young patient with locally advanced vulvar cancer, the treatment team arranged oocyte retrieval before starting therapy and modified the radiation plan to spare midline reproductive structures, successfully preserving fertility potential while still treating the cancer.22PubMed Central. Fertility-sparing treatment of locally advanced vulvar squamous cell carcinoma in a young patient This kind of approach requires close coordination between oncologists and fertility specialists, and it should be discussed early, before treatment begins, so that time-sensitive options like egg or embryo freezing are not missed.
Treatment Decisions in Older and Frail Patients
On the other end of the age spectrum, vulvar cancer disproportionately affects elderly women, many of whom have other health conditions that complicate treatment. A cohort study from a single center found that frailty, cognitive impairment, and functional dependency were all associated with treatment de-escalation. About half of the frail patients in that study received less intensive treatment than standard guidelines would recommend, with a geriatrician actively involved in weighing the potential benefit of aggressive treatment against the risk of serious complications.23PubMed. Frailty and treatment decisions in older patients with vulvar cancer: A single-center cohort study
De-escalation might mean performing a less radical excision, choosing radiation over surgery, or forgoing lymph node dissection in a patient whose life expectancy from other causes is limited. These are genuinely difficult decisions without clear-cut right answers, and they work best when made collaboratively between the patient, her family, the surgical oncologist, and a geriatric specialist who can assess what the patient’s body can realistically tolerate. Formal geriatric assessment is still not routine at most centers treating vulvar cancer, but the evidence increasingly supports making it part of the process for patients over 70 or those with significant comorbidities.